Introduction
Cross-border M&A has entered an era where geopolitical and regulatory considerations are not background variables but central determinants of deal feasibility and pricing. Cross-border deal value reached about $1.4 trillion in 2025, according to the XBMA annual review of LSEG data, yet that was only 30% of global M&A, below the ten-year average cross-border share of 34%, as domestic deals grew faster. Momentum built in 2026: LSEG counted $1.05 trillion of cross-border deals in January to July, the highest for that period since 2007, nearly half of it aimed at US and UK targets. Valuing a cross-border target requires adjustments that do not arise in purely domestic transactions.
Currency Risk: The Silent Valuation Mover
When a US-based acquirer values a European target, the offer price must account for the exchange rate between USD and EUR. The euro averaged about 1.08 dollars in 2023 and 2024, then rose roughly 13% during 2025, from 1.04 to 1.175 on the ECB euro reference rate. A target valued at €1 billion cost a US buyer about $1.04 billion at the start of 2025 and about $1.18 billion by year-end, with no change in its local-currency fundamentals. The weaker dollar worked the other way for European acquirers, cutting the euro cost of US targets by roughly 12%.
After closing, a stronger euro lifts a US acquirer's investment in dollar terms and a weaker one erodes it. Because the dollar cost of a euro offer can also move between signing and closing, acquirers often lock in the rate with a deal-contingent forward, a hedge that settles only if the deal completes.
For valuation, the analyst can build the DCF in the target's local currency or convert each year's EUR cash flow to USD at forward rates. The standard approach is to discount local-currency cash flows at the local WACC (using the relevant sovereign risk-free rate) and convert the resulting enterprise value at the spot rate. Mixing currencies (EUR cash flows discounted at a USD WACC) is wrong because cash flows and discount rate must share a currency.
- Country Risk Premium (CRP)
An additional return premium added to the cost of equity for companies in markets with elevated political, economic, or regulatory risk. The CRP is typically estimated from sovereign credit default swap (CDS) spreads or the yield spread between the country's sovereign bonds and US Treasuries. For a target in Brazil (CRP ~3-4%), the cost of equity in a DCF would be 3-4 percentage points higher than for a comparable US company. The CRP captures risks that beta does not: nationalization risk, currency inconvertibility, political instability, and weak rule of law.
Regulatory Fragmentation: Multiple Approval Hurdles
A domestic US M&A transaction requires approval from one antitrust authority (DOJ or FTC). A cross-border transaction may require approvals from the US (DOJ/FTC), the European Commission, the UK Competition and Markets Authority (CMA), China's SAMR, and other national regulators. Each authority applies its own standard, timeline, and remedies.
This regulatory fragmentation directly affects valuation because it introduces deal completion risk that must be priced into the analysis. A target that commands a $10 billion offer in a domestic context may warrant a lower offer in a cross-border deal because the probability of regulatory approval is lower and the timeline is longer (12-24 months for complex cross-border reviews versus 6-12 months domestically). The risk shows up as a lower bid or in structural provisions (reverse termination fees, regulatory ticking fees) that allocate it between the parties.
Tariffs and Trade Policy: The New Valuation Variable
The re-imposition and expansion of tariffs in 2025, alongside strengthened export controls on semiconductors, AI technology, and critical minerals, introduced a new dimension to cross-border valuation, and 2026 widened it. Section 232 proclamations added a 25% duty on certain advanced computing chips in January and a 100% tariff on patented pharmaceuticals in April (15% for EU, Japanese, Korean and Swiss products, 20% for companies with approved onshoring plans), which changes the math on pharmaceutical supply chain reshoring. The war with Iran added an energy shock: with Middle East oil flows constrained, Brent averaged $114 a barrel in September 2026, according to the EIA's October Short-Term Energy Outlook, repricing input and shipping costs for energy-intensive targets. Strategic technology deals also face national security review (CFIUS in the US, and EU member-state screening that a revised EU regulation makes mandatory from 2028).
For the analyst building a DCF for a cross-border target, tariff exposure must be modeled as a cost sensitivity: if a 10-15% tariff is imposed on the target's exports to a key market, how does that affect revenue and margins? If export controls restrict the target's ability to sell to Chinese customers, how does that affect the growth trajectory?
Accounting Standard Differences: GAAP vs. IFRS
US GAAP and IFRS produce different reported financials for the same underlying business, which affects comps and adjusted EBITDA calculations. Key differences include operating lease treatment (IFRS 16 inflates EBITDA relative to ASC 842), R&D capitalization (IFRS allows it in some cases; US GAAP expenses it), and revenue recognition timing. When a US peer group includes European IFRS reporters, the analyst must adjust for these differences to ensure the multiples are comparable.
